Conditions Precedent to the Obligations of the Purchaser and Sellers. Rowland served as executive vice president and chief financial officer, as well as the interim co-chief executive officer, for Endo Pharmaceuticals Inc. Corporate Organization and Qualification.
No Third-Party Beneficiaries. Absence of Undisclosed Liabilities. Shuda co-founded BlueLine Partners, which similarly focused on small public company investments.
- Rowland served as president and chief executive officer of Aurinia Pharmaceuticals Inc.
- Additional Excluded Assets.
- Seller Disclosure Schedule.
- DiIorio's year tenure with InfuSystem, he has received numerous awards and honors.
- Purchaser Disclosure Schedule.
Singleton previously served as an independent director of Salomon Reinvestment Company Inc. Macartney was employed at Astra Pharmaceuticals from to in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc. Conduct of Business of Sellers.
Assumed Leased Real Property. Matthew Singleton is Independent Director of the Company. He was Independent Director of the Company. The following summary of the Plan is not intended to be a complete description of the Plan.
Asset Purchase Agreement
Most Recent Balance Sheet. After serving in Vietnam, Mr. In the event Sellers do not resolve such discrepancy with such Contract party in question, then, Sellers shall deliver such Excess Cure Amount to the Contract parties in question. Assumed Independent Contractor Contracts.
HearUSA Plan Effective
Foehr is the author of multiple scientific publications and is named on numerous U. Search for free - click here. Yetter began his career in the pharmaceuticals industry in as a sales representative for Pfizer. Purchase and Sale of Assets.
Ligand Pharmaceuticals, Inc. Naval Academy Athletic Foundation. Rouan is serving as a non-executive Board member at Navidea Pharmaceuticals, Inc.
Prior to co-founding Meridian, Mr. Siemens Hearing Instruments, Inc. Foehr is Director of the Company. Eastern Time on the Closing Date. The Bankruptcy Court also gave final approval of a disclosure statement prepared by the Company describing the Plan.
InfuSystem Holdings Inc (INFU.A)
Assumed Intellectual Property. Whitters has also been an advisor or board member with several private companies. Conditions Precedent to the Obligations of the Purchaser.
The Liquidating Trust will also serve to settle the final taxes after the Effective Date. Dreyer served in related senior financial management positions within the pharmaceutical industry, working for Elan Corporation plc, Athena Neurosciences and Syntex. Shuda was an executive officer of publicly-traded Vicinity Corporation, and prior to that worked as a transactions-related attorney in New York City and Silicon Valley. Schulte held various positions as Chief Financial Officer, Vice President and Corporate Controller at various public and private equity-owned corporations. Whitters was employed in various capacities with First Health Group Corp.
Asset Purchase Agreement
- Prior to joining the Company, Mr.
- Yetter has built and led a variety of multi-million dollar businesses and pharmaceutical operations for some of the largest companies in the world.
- Prior to joining Innocur, Mr.
- Montgomery previously served on the Board of Directors of Daegis, Inc.
- For the avoidance of doubt, none of the Excluded Liabilities shall be Assumed Liabilities.
Closing Deliveries by the Purchaser. Whitters is a certified public accountant. Conditions Precedent to the Obligations of Sellers. Sansone holds voting and dispositive power over the Common Stock held by the Sansone Group. Webster is Independent Director of the Company.
Asset Purchase Agreement - Husa Liquidating Corp - 8/24
Jurisdiction, Waiver of Jury Trial. Sansone is Director of the company. Deposits and Prepaid Expenses.
Asset Purchase Agreement
That financial information is incorporated herein by this reference. At Stiefel Laboratories, Inc. Morris currently serves on the Board of Directors of Sevcon, Inc.
Rowland previously held positions of increasing responsibility at Biovail Pharmaceuticals, Inc. Authority Relative to This Agreement. Search Documents Browse Documents. Notice of Default under Material Contracts. Additional Assumed Liabilities.
Prior to joining Optimer, Mr. Consents of Third Parties. Closing Deliveries by Sellers. Shuda serves as Chairman of the Board of the Company. Singleton served as a director of Cubist Pharmaceuticals Inc.
Montgomery formerly served on active duty as a U. The summary is qualified in its entirety by reference to the Plan. No Due Diligence Contingency. Montgomery is Director of the company. Assumed Intellectual Property Licenses.
All capitalized terms not defined herein shall have the meaning ascribed to them in the Plan. Assumed Personal Property Leases. Frustration of Closing Conditions. Welfare Benefits under Assumed Plans.
In such capacity, he frequently serves as a member of the board of directors of portfolio companies. Prior to this appointment, Mr. Prior to joining Sicor, Mr. Further Conveyances and Assumptions. Accrued Employee Obligations.
Dreyer led the sale of Sicor, Inc. He brings extensive investment experience as both a managing partner and founder of an investment partnership and various executive leadership roles throughout his career. Procedure Upon Termination. This is a document preview.
Competing Bid and Other Matters. Rowland joined the board of directors of Idenix Pharmaceuticals, Inc. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, dating a biotechnology company. Assumed Real Property Leases. Certain capitalized terms used herein are defined in Article I.